ADAP
Adaptimmune Therapeutics
ADAP
ADAP
Delisted
ADAP was delisted on the 27th of October, 2025.
68 hedge funds and large institutions have $299M invested in Adaptimmune Therapeutics in 2019 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 22 increasing their positions, 16 reducing their positions, and 19 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more ownership
Funds ownership: →
less funds holding
Funds holding: →
less capital invested
Capital invested by funds: $ → $
63% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 19
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
85% less call options, than puts
Call options by funds: $6K | Put options by funds: $41K
Holders
68
Holding in Top 10
1
Calls
$6K
Puts
$41K
Top Buyers
| 1 | +$3.66M | |
| 2 | +$2.11M | |
| 3 | +$1.27M | |
| 4 |
Morgan Stanley
New York
|
+$807K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$774K |
Top Sellers
| 1 | -$4.03M | |
| 2 | -$3.26M | |
| 3 | -$1.44M | |
| 4 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$754K |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$748K |